Study design
Cancer
CANCER
The IPRICE study is a single-center, prospective, non-randomized, open-label, and interventional clinical trial of patients managed at the Cancer Institute of Strasbourg (ICANS) Europe (Strasbourg). Study inclusion period will be 3 years; each patient will be followed up for 3 years and the total study duration will be 6 years. The study design is depicted in Fig. IPRICE study design